The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Cyclosporine before PCI in Patients with Acute Myocardial Infarction
Open accessAbstract
BACKGROUND: Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODS: In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTS: A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval [CI], 0.78 to 1.39; P=0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONS: In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with relatively deceiving results (despite multiple clinical trials, no drug based on this concept has ever been approved for use in humans by regulatory agencies) [387].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [387]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Authors Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Mario, C. D., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,890
Self-citationYellon, D. M., & Hausenloy, D. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071667 · Cited by 3,797
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., & Tsujimoto, Y. (2005) · Nature · doi:10.1038/nature03317 · Cited by 1,635
Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction
Piot, C. A., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., Belghiti, R. E., Cung, T. T., Bonnefoy‐Cudraz, E., Angoulvant, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071142 · Cited by 1,339
Self-citationEvolving Therapies for Myocardial Ischemia/Reperfusion Injury
Ibáñez, B., Heusch, G., Ovize, M., & de Werf, F. V. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.032 · Cited by 1,014
Self-citationMitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion
Griffiths, E. J., & Halestrap, A. P. (1995) · Biochemical Journal · doi:10.1042/bj3070093 · Cited by 838
Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy
Jolly, S. S., Cairns, J. A., Yusuf, S., Meeks, B., Pogue, J. M., Rokoss, M. J., Kedev, S. A., Thabane, L., Stankovic, G. R., Moreno, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415098 · Cited by 665
Self-citationSteg, P. G., Greenlaw, N., Tardif, J., Tendera, M., Ford, I., Kääb, S., Abergel, H., Fox, K. M., Ferrari, R., & on behalf of the CLARIFY Registry Investigators (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs289 · Cited by 653
Self-citationHausenloy, D. J. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00455-8 · Cited by 585
Ferdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F., & Schulz, R. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008300 · Cited by 568
Stone, G. W. (2012) · JAMA · doi:10.1001/jama.2012.421 · Cited by 542
Ovize, M., Baxter, G. F., Lisa, F. D., Ferdinandy, P., David Garcia-dorado, A., Hausenloy, D. J., Heusch, G., Vinten-Johansen, J., Yellon, D. M., & Schulz, R. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq129 · Cited by 502
Self-citationIbáñez, B., Macaya, C., Sánchez-Brunete, V., Pizarro, G., Fernández‐Friera, L., Rodríguez, A. A. M., Fernández‐Ortíz, A., García-Ruiz, J. M., García‐Álvarez, A., Íñiguez, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.003653 · Cited by 395
On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury
Duchen, M. R., McGuinness, O. M., Brown, L. A., & Crompton, M. (1993) · Cardiovascular Research · doi:10.1093/cvr/27.10.1790 · Cited by 294
The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE
Fox, K. A. A., Eagle, K. A., Gore, J. M., Steg, P. G., Anderson, F. A., & for the GRACE and GRACE2 Investigators (2010) · Heart · doi:10.1136/hrt.2009.190827 · Cited by 272
Self-citationSavoye, C., Equine, O., Tricot, O., Nugue, O., Segrestin, B., Sautière, K., Elkohen, M., Pretorian, E.-M., Taghipour, K., Philias, A., et al. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.011 · Cited by 189
Crompton, M., & COSTI, A. (1990) · Biochemical Journal · doi:10.1042/bj2660033 · Cited by 173
Ortiz-Pérez, J. T., Meyers, S. N., Lee, D. C., Kansal, P., Klocke, F. J., Holly, T. A., Davidson, C. J., Bonow, R. O., & Wu, E. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm212 · Cited by 167
Cyclosporine A at Reperfusion Reduces Infarct Size in Pigs
Skyschally, A., Schulz, R., & Heusch, G. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6219-y · Cited by 119
Li, J., Iorga, A., Sharma, S., Youn, J.-Y., Partow-Navid, R., Umar, S., Cai, H. “., Rahman, S., & Eghbali, M. (2012) · Anesthesiology · doi:10.1097/aln.0b013e3182655e73 · Cited by 84
David Garcia-dorado, A., del Blanco, B. G., Otaegui, I., Rodríguez-Palomares, J. F., Pineda, V., Gimeno, F., Ruiz-Salmeron, R. J., Elı́zaga, J., Evangelista, A., Fernández‐Avilés, F., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.203 · Cited by 81
Ghaffari, S., Kazemi, B., Toluey, M., & Sepehrvand, N. (2012) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12010 · Cited by 68
Lim, W. Q. M., Messow, C., & Berry, C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01691.x · Cited by 67
Hausenloy, D. J., Kunst, G., Boston‐Griffiths, E., Kolvekar, S. K., Chaubey, S., John, L. C. H., Desai, J., & Yellon, D. M. (2014) · Heart · doi:10.1136/heartjnl-2013-304845 · Cited by 66
Cyclosporine Protects the Heart during Aortic Valve Surgery
Chiari, P. C., Angoulvant, D., Mewton, N., Desebbe, O., Obadia, J., Robin, J., Farhat, F., Jegaden, O., Bastien, O. H., Lehot, J.-J., et al. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000331 · Cited by 57
Self-citationCyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart
Paulis, D. D., Chiari, P. C., Teixeira, G., Couture-Lepetit, E., Abrial, M., Argaud, L., Gharib, A., & Ovize, M. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0379-4 · Cited by 46
Self-citationSanchez, H., Zoll, J., Bigard, X. A., Veksler, V., Mettauer, B., Lampert, E., Lonsdorfer, J., & Ventura‐Clapier, R. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704129 · Cited by 45
Khan, A. R., Abdulhak, A. A. B., Alastal, Y., Khan, S., Faricy-Beredo, B., Luni, F. K., Lee‐Smith, W., Khuder, S., & Tinkel, J. L. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.06.021 · Cited by 42
Zalewski, J., Claus, P., Bogaert, J. G., Driessche, N. V., Driesen, R. B., Galan, D. T., Sipido, K. R., Buszman, P. P., Milewski, K. P., & de Werf, F. V. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0475-8 · Cited by 42
Cohen, M. V., & Downey, J. M. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413508465 · Cited by 42
Mewton, N., Cung, T. T., Morel, O., Cayla, G., Bonnefoy‐Cudraz, E., Rioufol, G., Angoulvant, D., Guérin, P., Elbaz, M., Delarche, N., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.020 · Cited by 40
Self-citationEhinger, J. K., Hansson, M. J., Sjövall, F., & Elmér, E. (2012) · Clinical Drug Investigation · doi:10.1007/s40261-012-0029-x · Cited by 22
Self-citationPuymirat, É., Aïssaoui, N., Cottin, Y., Vanzetto, G., Carrié, D., Isaaz, K., Valy, Y., Tchétché, D., Schiele, F., Steg, P. G., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.08.039 · Cited by 12
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective
Heusch, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0403-y · Cited by 1,271
Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease
Re, D. P. D., Amgalan, D., Linkermann, A., Liu, Q., & Kitsis, R. N. (2019) · Physiological Reviews · doi:10.1152/physrev.00022.2018 · Cited by 994
Mitochondrial dysfunction and oxidative stress in heart disease
Peoples, J. N., Saraf, A., Ghazal, N., Pham, T. T., & Kwong, J. Q. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0355-7 · Cited by 950
The machineries, regulation and cellular functions of mitochondrial calcium
Giorgi, C., Marchi, S., & Pinton, P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0052-8 · Cited by 941
Metadata
- Authors
- Cung, T.-T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., Bonnefoy-Cudraz, E., Guérin, P., Elbaz, M., Delarche, N., Coste, P., Vanzetto, G., Metge, M., Aupetit, J.-F., Jouve, B., Motreff, P., Tron, C., Labeque, J.-N., Steg, P. G., Cottin, Y., Range, G., Clerc, J., Claeys, M. J., Coussement, P., Prunier, F., Moulin, F., Roth, O., Belle, L., Dubois, P., Barragan, P., Gilard, M., Piot, C., Colin, P., De Poli, F., Morice, M.-C., Ider, O., Dubois-Randé, J.-L., Unterseeh, T., Le Breton, H., Béard, T., Blanchard, D., Grollier, G., Malquarti, V., Staat, P., Sudre, A., Elmer, E., Hansson, M. J., Bergerot, C., Boussaha, I., Jossan, C., Derumeaux, G., Mewton, N., & Ovize, M.
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Lyon 1 Université (FR)
- Centre Hospitalier De Pau (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Saint-Joseph Saint-Luc (FR)
- Centre Hospitalier Intercommunal Aix-Pertuis (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Hôpital Charles-Nicolle (FR)
- CHU Dijon Bourgogne (FR)
- Antwerp University Hospital (BE)
- AZ Sint-Jan (BE)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier de Mulhouse (FR)
- HUmani - CHU Charleroi-Chimay (BE)
- Clinique du Millénaire (FR)
- Hôpital Privé Jacques Cartier (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Lille’s Cardiology Hospital (FR)
- Lund University (SE)
- ORCID
- Morel, Olivier
- Cayla, Guillaume
- Rioufol, Gilles
- Angoulvant, Denis
- Guérin, Patrice
- Delarche, Nicolas
- Coste, Pierre
- Motreff, Pascal
- Tron, Christophe
- Cottin, Yves
- Claeys, Marc J.
- Prunier, Fabrice
- Barragan, Paul
- Gilard, Martine
- Piot, Christophe
- Unterseeh, Thierry
- Sudre, Arnaud
- Hansson, Magnus J.
- Bergerot, Cyrille
- Jossan, Claire
- Mewton, Nathan
- Ovize, Michel
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-09-10
- Volume
- 373
- Issue
- 11
- Pages
- 1021-1031
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2200357463
- Cited by
- 713
- References
- 34
- Citations by year
- 2026: 38 · 2025: 46 · 2024: 48 · 2023: 55 · 2022: 62 · 2021: 57 · 2020: 75 · 2019: 79 · 2018: 70 · 2017: 70 · 2016: 92 · 2015: 20
- FWCI
- 66.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Lunds Universitet
- Assistance publique-Hôpitaux de Paris
- Universitair Ziekenhuis Antwerpen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- cyclosporine, ST-elevation myocardial infarction, percutaneous coronary intervention, left ventricular remodeling, ischemia-reperfusion injury, myocardial infarct size, heart failure, intravenous cyclosporine, primary percutaneous coronary intervention, drug safety
- MeSH terms
- Peptidyl-Prolyl Isomerase D, Aged, Combined Modality Therapy, Double-Blind Method, Electrocardiography, Enzyme Inhibitors, Female, Heart Failure, Humans, Injections, Intravenous, Male, Middle Aged, Mortality, Myocardial Infarction, Cyclosporine, Ventricular Remodeling, Cyclophilins, Kaplan-Meier Estimate, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
